Vasculopathy in patients with Fabry disease : current controversies and research directions

Rombach, S.M.; Twickler, Th. B.; Aerts, J.M.F.G.; Linthorst, G.E.; Wijburg, F.A.; Hollak, C.E.M.

doi:10.1016/J.YMGME.2009.10.004

Title

Vasculopathy in patients with Fabry disease : current controversies and research directions

Author

Rombach, S.M.

Twickler, Th. B.

Aerts, J.M.F.G.

Linthorst, G.E.

Wijburg, F.A.

Hollak, C.E.M.

Abstract

Fabry disease is an X-linked lysosomal storage disorder due to deficiency of the enzyme alpha-galactosidase A. The principal clinical manifestations of Fabry disease consist of cardiovascular complications including cerebrovascular, renal and cardiac disease but the pathophysiology of this specific vasculopathy is unclear. With the development of targeted treatment for Fabry disease, i.e. enzyme replacement therapy, it has become apparent that the removal of stored glycosphingolipid from the enclothelial cells does not prevent progression of vascular disease in many patients. The aim of this study is to review the current available literature on vascular function tests, imaging and pathology studies and propose a hypothesis on the evolution of arterial complications in Fabry disease. Clearly, although premature atherosclerosis is suggested to occur, most studies describe absence of characteristic plaque formation. Smooth muscle cell hypertrophy, is probably the earliest feature of a complex vasculopathy, as in females and atypical cardiac variants, who have residual enzyme activity, no enclothelial storage of significance is found. Subsequently, processes occur as observed in neo intima formation however with formation of more fibrotic structures. In the presence of a hyperdynamic circulation in combination with a less compliant vascular wall, it is hypothesized that upregulation of local renin angiotensine systems may occur. Angiotensin II is known to increase adhesion molecules, cytokines and chemokines and exerts a pro-inflammatory effect on leucocytes, enclothelial cells and vascular smooth muscle cells. This enhances release of pro-thrombotic factors and opposes actions mediated through angiotensin 2 (AT2) receptor, including the release of nitric oxide (NO). A combination of reduced Vascular compliance and activation of pro-thrornbotic factors can lead to vascular complications in Fabry disease.

Language

English

Source (journal)

Molecular genetics and metabolism. - Orlando, Fla

Publication

San diego : Academic press inc elsevier science , 2010

ISSN

1096-7192

DOI

10.1016/J.YMGME.2009.10.004

Volume/pages

99 :2 (2010) , p. 99-108